Sea Sponge-Inspired drug fights rare aggressive cancers
NCT ID NCT03331250
Summary
This study is testing whether the drug eribulin can help control two rare types of blood vessel cancers: angiosarcoma and epithelioid hemangioendothelioma (EHE). The trial involves adults whose cancer has continued to grow despite previous treatments. Researchers want to see if this medication, originally inspired by a sea sponge compound, can shrink tumors or stop their growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.